Diagnostic Utility of Separate Anti-Ro60 and Anti-Ro52/TRIM21 Antibody Detection in Autoimmune Diseases.
Adolescent
Adult
Aged
Aged, 80 and over
Antibodies, Antinuclear
/ blood
Antibodies, Antiphospholipid
/ blood
Autoantigens
/ blood
Autoimmune Diseases
/ immunology
Female
France
Humans
Lupus Erythematosus, Systemic
/ immunology
Male
Middle Aged
Myositis
/ immunology
RNA, Small Cytoplasmic
/ blood
Retrospective Studies
Ribonucleoproteins
/ blood
Scleroderma, Systemic
/ immunology
Sjogren's Syndrome
/ immunology
Young Adult
TRIM21
anti-Ro52 antibodies
anti-Ro60 antibodies
anti-SSA antibodies
autoimmune diseases
connective tissue disease
primary Sjögren's syndrome
systemic lupus
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2019
2019
Historique:
received:
10
07
2018
accepted:
19
02
2019
entrez:
28
3
2019
pubmed:
28
3
2019
medline:
8
9
2020
Statut:
epublish
Résumé
Anti-SS-A antibodies are often sought for in autoimmune diseases diagnosis. Two different target proteins have actually been identified: Ro52 and Ro60. Clinical and immunological associations seem different depending on anti-Ro52 or anti-Ro60 antibodies presence. However, due to a heterogeneous presentation in the literature, some immunology laboratories in France have stopped providing anti-Ro52 antibody findings. We report here a new hospital study designed to determine the diagnostic utility of the separate detection of anti-Ro52 and anti-Ro60 antibodies. We conducted a retrospective, observational study, including every adult patient with positive antinuclear antibodies (ANA) tested in our immunology laboratory, and associated with anti-Ro52 and/or anti-Ro60 antibodies, between 2011 and 2014. Out of 13032 sera tested for ANA, 399 adults had antibodies to Ro52 and/or Ro60; 81.7% were female, with a mean age of 54.5 ± 17.0 years. Anti-Ro52 antibodies were found in 75.7% of the patients and anti-Ro60 antibodies in 56.9%. Among them, 43.1% were classified in the Ro52 + Ro60- group, 32.6% in the Ro52 + Ro60 + group and 24.3% in the Ro52-Ro60+ group. In the Ro52-Ro60+ group, systemic lupus was the most frequent diagnosis (48.5%), with a possible association with antiphospholipid antibodies (anti-cardiolipin antibodies: OR 2.5 (CI95 [1.0-5.0],
Identifiants
pubmed: 30915082
doi: 10.3389/fimmu.2019.00444
pmc: PMC6423153
doi:
Substances chimiques
Antibodies, Antinuclear
0
Antibodies, Antiphospholipid
0
Autoantigens
0
RNA, Small Cytoplasmic
0
RO60 protein, human
0
Ribonucleoproteins
0
SS-A antibodies
0
SS-A antigen
0
anti-extractable nuclear antigen antibodies
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
444Références
Autoimmunity. 2000 Sep;32(2):89-92
pubmed: 11078154
Clin Diagn Lab Immunol. 2001 Sep;8(5):922-5
pubmed: 11527804
Ann Rheum Dis. 2002 Oct;61(10):929-33
pubmed: 12228166
Scand J Immunol. 2002 Nov;56(5):456-69
pubmed: 12410795
Ann Rheum Dis. 2002 Dec;61(12):1090-4
pubmed: 12429541
Rev Med Interne. 2004 Jun;25(6):421-8
pubmed: 15158312
Curr Opin Rheumatol. 2004 Sep;16(5):534-40
pubmed: 15314490
Autoimmun Rev. 2006 Jul;5(6):367-72
pubmed: 16890888
Lupus. 2007;16(1):10-7
pubmed: 17283579
J Clin Pathol. 2007 Jun;60(6):670-3
pubmed: 17557869
Arthritis Res Ther. 2007;9(4):R78
pubmed: 17688695
Mod Rheumatol. 2008;18(2):153-60
pubmed: 18283522
Autoimmun Rev. 2008 Feb;7(4):272-7
pubmed: 18295729
N Engl J Med. 2008 Feb 28;358(9):929-39
pubmed: 18305268
Autoimmun Rev. 2009 Jun;8(7):632-7
pubmed: 19393201
Rheumatology (Oxford). 2009 Aug;48(8):964-7
pubmed: 19531627
J Exp Med. 2009 Aug 3;206(8):1661-71
pubmed: 19635858
J Clin Invest. 1991 Feb;87(2):379-83
pubmed: 1991824
Postgrad Med J. 2010 Feb;86(1012):79-82
pubmed: 20145055
Autoimmun Rev. 2011 Jan;10(3):123-5
pubmed: 20833272
Autoimmun Rev. 2011 Jan;10(3):150-4
pubmed: 20854935
Arthritis Rheum. 1990 Mar;33(3):349-55
pubmed: 2107806
Rheumatol Int. 2012 Feb;32(2):491-5
pubmed: 21246358
Autoimmun Rev. 2011 Jul;10(9):509-13
pubmed: 21447407
Arthritis Res Ther. 2012 Mar 06;14(2):R50
pubmed: 22394602
J Autoimmun. 2012 Aug;39(1-2):77-82
pubmed: 22402340
Arthritis Res Ther. 2012 Apr 26;14(2):208
pubmed: 22546326
Clin Exp Rheumatol. 2012 Sep-Oct;30(5):686-92
pubmed: 22704838
Autoimmunity. 2013 Feb;46(1):32-9
pubmed: 23039326
Nat Immunol. 2013 Feb;14(2):172-8
pubmed: 23222971
J Immunol. 2013 Oct 1;191(7):3753-63
pubmed: 23975864
ScientificWorldJournal. 2013 Oct 30;2013:832789
pubmed: 24294139
Annu Rev Immunol. 1987;5:109-26
pubmed: 2439101
Immunol Lett. 2014 Sep;161(1):6-12
pubmed: 24768604
Clin Exp Rheumatol. 2014 Nov-Dec;32(6 Suppl 86):S-177-82
pubmed: 25372801
Nat Rev Rheumatol. 2015 May;11(5):301-12
pubmed: 25800217
Clin Exp Rheumatol. 2015 Jul-Aug;33(4 Suppl 91):S131-5
pubmed: 26315678
Rheumatology (Oxford). 2016 Jan;55(1):103-8
pubmed: 26320136
Mod Rheumatol. 2016;26(3):403-9
pubmed: 26344678
Front Immunol. 2015 Aug 20;6:412
pubmed: 26347739
Reumatol Clin. 2016 Sep-Oct;12(5):256-62
pubmed: 26725021
Circ Arrhythm Electrophysiol. 2016 Apr;9(4):e003419
pubmed: 27030700
J Rheumatol. 2016 Aug;43(8):1566-74
pubmed: 27252419
J Clin Invest. 1989 Aug;84(2):627-34
pubmed: 2760204
Rheumatol Int. 2017 Aug;37(8):1323-1333
pubmed: 28417151
Front Immunol. 2017 May 31;8:651
pubmed: 28620393
J Clin Pathol. 2018 Jan;71(1):12-19
pubmed: 28663326
Mod Rheumatol. 2018 Jul;28(4):690-696
pubmed: 28880700
Front Immunol. 2018 Mar 26;9:541
pubmed: 29632529
Arthritis Rheum. 1994 Jan;37(1):88-92
pubmed: 8129768
Immunol Invest. 1993 Apr;22(3):189-203
pubmed: 8509157